A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Daiichi Sankyo logo

Daiichi Sankyo

Status and phase

Begins enrollment this month
Phase 2
Phase 1

Conditions

Extensive Stage-small Cell Lung Cancer

Treatments

Drug: Ifinatamab deruxtecan
Drug: Carboplatin
Drug: Etoposide
Drug: Atezolizumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT06362252
2023-509629-36 (Other Identifier)
DS7300-189

Details and patient eligibility

About

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

Full description

This study consists of two parts and two cohorts: Part A (Phase 1b; Safety Run-in) and Part B (Phase 2; Dose Optimization), Cohort 1 (I-DXd in maintenance) and Cohort 2 (I-DXd in induction + maintenance). The primary objective of this study is to evaluate the safety and tolerability of I-DXd in combination with atezolizumab with or without carboplatin by assessing treatment-emergent adverse events (TEAEs) and other safety parameters which will inform optimal dose selection of I-DXd in the combination regimens (Dose Optimization Part B) of this study.

Enrollment

149 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Participants must meet all of the following criteria to be eligible for enrollment into the study:

  • Sign and date the informed consent form (ICF), prior to the start of any study-specific qualification procedures.
  • Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.
  • Has histologically or cytologically confirmed diagnosis of ES-SCLC who will require first-line therapy.
  • For Cohort 1 Part A, participant has received 4 cycles of 1L induction therapy with carboplatin, etoposide, and atezolizumab for ES-SCLC with ongoing CR PR, CR, or SD per RECIST v1.1 assessed by the investigator.
  • For Cohort 1 Part B and Cohort 2, participant has received no prior treatment for ES-SCLC.

5. For Cohort 1 Part B and Cohort 2, participant has at least one measurable lesion according to RECIST v1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by the investigator.

6. For Cohort 1 Part B and Cohort 2, participant must have at least one lesion, amenable to core biopsy, and must consent to provide a pretreatment biopsy tissue sample and on-treatment biopsy.

7. Has ECOG PS of ≤1 (assessed within 7 days before enrollment/randomization). 8. Has adequate organ function within 7 days before the start of study treatment as specified in the study protocol.

9. If the participant is a female of childbearing potential, she must have a negative serum pregnancy test during Screening (within 28 days prior to randomization). Male and female participants of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug.

10. Male participants must not freeze or donate sperm starting at enrollment/randomization, throughout the Treatment Period, and for at least 4 months following the last dose of the study drug. Preservation of sperm may be considered prior to enrollment/randomization.

11. Female participants must not donate, or retrieve for their own use, ova from the time of enrollment/randomization and throughout the Treatment Period and for at least 7 months following the last dose of the study drug.

12. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  • Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
  • Prior discontinuation of an ADC that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
  • Has received prior treatment with CD137 agonists or ICIs, including anti- cytotoxic T-cell lymphocyte-4 (CTLA-4), anti-PD-1, and anti-PD-L1 therapeutic antibodies, except for atezolizumab for Cohort 1 Part A.
  • Has inadequate washout period before enrollment/randomization as specified in the study protocol.
  • Has any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event.
  • Has clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.
  • Has clinically significant corneal disease.
  • Has uncontrolled or significant cardiovascular disease,.
  • Has history of (non-infectious) ILD/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • Is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease, topical steroids (for mild skin conditions), or intra-articular steroid injections.
  • Has history of malignancy other than SCLC within the 5 years prior to randomization/enrollment, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial gastrointestinal tract tumors, and non-muscle invasive bladder cancer curatively resected by endoscopic surgery.
  • Has history of allogeneic bone marrow, stem cell, or solid organ transplant.
  • Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE V5.0, Grade ≤1 or baseline.
  • Has history of hypersensitivity to the drug substances, inactive ingredients in the drug product or severe hypersensitivity reactions to other monoclonal antibodies.
  • Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
  • Has known human immunodeficiency virus (HIV) infection that is not well controlled.
  • Has active or uncontrolled hepatitis B or C infection.
  • Has history of autoimmune disease.
  • Has any evidence of severe or uncontrolled systemic diseases.
  • Has received a live vaccine within 30 days prior to the first dose of study drug.
  • Is a female who is pregnant or breastfeeding or planning to become pregnant.
  • Has prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
  • Has psychological, social, familial, or logistical factors that would prevent regular follow-up

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

149 participants in 7 patient groups

Cohort 1, Part A: Maintenance Only (I-DXd 12 mg/kg)
Experimental group
Description:
Part A (Safety Run-in): Participants who must have completed 1L induction with 4 cycles of standard of care (SoC) with best overall response of CR, PR, or SD will receive maintenance therapy only (I-DXd 12 mg/kg IV Q3W + atezolizumab 1200 mg IV Q3W). A 5-day surveillance period between each of the first 3 participants (up to a maximum of 9 participants) dosed is included as a safety measure.
Treatment:
Drug: Atezolizumab
Drug: Ifinatamab deruxtecan
Cohort 2, Part A: Induction + Maintenance (I-DXd 8 mg/kg)
Experimental group
Description:
Part A (Safety Run-in): Participants who are treatment-naive with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 IV Q3W) followed by maintenance therapy (I-DXd 8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W).
Treatment:
Drug: Atezolizumab
Drug: Carboplatin
Drug: Ifinatamab deruxtecan
Cohort 2, Part A: Induction + Maintenance (I-DXd 12 mg/kg)
Experimental group
Description:
Part A (Safety Run-in): Participants who are treatment-naive with ES-SCLC will receive 4 cycles of I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 IV Q3W) followed by maintenance therapy (I-DXd 12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W).
Treatment:
Drug: Atezolizumab
Drug: Carboplatin
Drug: Ifinatamab deruxtecan
Cohort 1, Part B: SoC Induction + Maintenance (I-DXd 8 mg/kg)
Experimental group
Description:
Part B (Dose Optimization): Participants who are treatment naive with ES-SCLC will receive 4 cycles of 1L SoC induction therapy (carboplatin AUC 5 IV Q3W, etoposide 100 mg/m^2 IV Q3W, and atezolizumab 1200 mg IV Q3W) and only those patients with best overall response of CR, PR, or SD after completion of the induction will be re-randomized to maintenance therapy (I-DXd 8 mg/kg IV Q3W + atezolizumab 1200 mg IV Q3W).
Treatment:
Drug: Atezolizumab
Drug: Etoposide
Drug: Carboplatin
Drug: Ifinatamab deruxtecan
Cohort 1, Part B: SoC Induction + Maintenance (I-DXd 12 mg/kg)
Experimental group
Description:
Part B (Dose Optimization): Participants who are treatment naive with ES-SCLC will receive 4 cycles of 1L SoC induction therapy (carboplatin AUC 5 IV Q3W, etoposide 100 mg/m^2 IV Q3W, and atezolizumab 1200 mg IV Q3W) and only those patients with best overall response of CR, PR, or SD after completion of the induction will be re-randomized to maintenance therapy (I-DXd 12 mg/kg IV Q3W + atezolizumab 1200 mg IV Q3W).
Treatment:
Drug: Atezolizumab
Drug: Etoposide
Drug: Carboplatin
Drug: Ifinatamab deruxtecan
Cohort 2, Part B: Induction + Maintenance (I-DXd 8 mg/kg)
Experimental group
Description:
Participants who are treatment-naive with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 IV Q3W) followed by maintenance therapy (I-DXd 8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W).
Treatment:
Drug: Atezolizumab
Drug: Carboplatin
Drug: Ifinatamab deruxtecan
Cohort 2, Part B: Induction + Maintenance (I-DXd 12 mg/kg)
Experimental group
Description:
Participants who are treatment-naive with ES-SCLC will receive 4 cycles of I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 IV Q3W) followed by maintenance therapy (I-DXd 12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W).
Treatment:
Drug: Atezolizumab
Drug: Carboplatin
Drug: Ifinatamab deruxtecan

Trial contacts and locations

0

Loading...

Central trial contact

(US) Daiichi Sankyo Contact for Clinical Trial Information; (Asia) Daiichi Sankyo Contact for Clinical Trial Information

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems